extended half-life (EHL) products, the chromogenic assay is increasingly the assay of choice for potency labelling of FVIII concentrates worldwide. 2 There are many publications describing differences between onestage and chromogenic assays in post-infusion samples. Differences can be observed of up to 40% for full-length recombinant products. [3] [4] [5] [6] [7] This can be abolished by use of a concentrate standard for assay calibration. 8 In earlier studies, results of chromogenic assays have been up to 50% higher than those obtained by one-stage assay for some B-domain deleted (BDD) FVIII products with standard halflives. 5, 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] The laboratory reagents used in the assay have an impact on these differences, 7, 9, 15, 17 and use of the ReFacto AF laboratory standard (RLS) for one-stage assay calibration has been shown to deliver agreement with chromogenic results. 7, [10] [11] [12] [13] [14] Use of the RLS for assay calibration is routine in some countries. 7 Guidance from SSC of ISTH has suggested that the optimal approach to post-infusion testing of FVIII and FIX concentrates should involve assaying against a product-specific standard composed of the same material as that used for treatment 18 but the same manuscript recognized that this may be difficult to implement.
Recently, a BDD recombinant FVIII covalently linked to the human IgG 1 Fc domain (rFVIIIFc) with extended half-life 19 has been developed and licensed for use in some regions. This product is labelled as Eloctate in the United States and Elocta in Europe, and is potency labelled using a chromogenic assay. 20 In a field study utilizing spiked samples, results of chromogenic assay were up to 26% higher than those obtained by one-stage methods. 21 There were no clinically important differences between results obtained using different reagent sets in the one-stage or chromogenic assay. Not all available reagent sets were included amongst the participating centres and it is not known whether samples prepared by in vitro mixing of concentrate and FVIII deficient plasma (spiked samples)
can successfully replace samples collected from patients after infusion of concentrate (ie, are commutable). Furthermore, some diagnostic companies make changes to their reagents from time to time, so regular reassessment of FVIII assays for post-infusion monitoring is required as part of the postmarketing surveillance that ensures patient safety. Proficiency testing programmes such as UK NEQAS BC are a convenient way to provide such surveillance.
The present study involved analysis of both spiked and postinfusion samples from haemophilia A patients containing Advate or rFVIIIFc by haemophilia centres in the UK and Scandinavia who were invited to perform their FVIII assays as they would be used in routine patient monitoring. Details of their current practice in relation to FVIII assays and concentrate usage were also requested.
| ME THODS
This exercise comprised four samples as follows Samples 2 and 4 were prepared using the same FVIII deficient plasma from a severe haemophilia A patient with normal VWF content (HRF, Chapel Hill, NC) with in vitro addition of Advate (sample 2) or Elocta (sample 4). Advate was purchased in Europe (Shire, UK). Elocta was a kind gift of Sobi, Stockholm, Sweden. Potencies of Advate 22 and Elocta/Eloctate 20 for all four samples had been assigned by the product manufacturer using chromogenic assays.
The labelled potency of the concentrates was used to calculate how much concentrate to add to FVIII deficient plasma so that the spiked samples would have similar levels of chromogenic FVIII activity to the post-infusion samples, but no potency was assigned to test samples in advance of distribution to participating centres.
All four samples were buffered with 0.8 g% HEPES and 1.0 g% glycine, and then lyophilized to allow distribution at room temperature. Stability of such samples is excellent. 23 Samples were sent to 67 centres in the UK and seven in Scandinavia in spring 2016.
Participants performed FVIII assays using their routine assay method including their routine assay calibration process used when monitoring post-concentrate samples containing these products. Centres who maintained both one-stage and chromogenic assays were asked to perform both.
Participants were also asked to provide details of their FVIII assay procedure for each type of product.
| Statistical analysis
Results obtained by chromogenic or one-stage assay were compared using an unpaired t test as were one-stage FVIII assay results obtained by the two most commonly used commercial reagent sets.
| RE SULTS
Responses and FVIII assay results were received from a total of 58 centres.
| One-stage FVIII assay results with different reagents
In total, nine different APTT reagents were used in one-stage assays. Results grouped according to which APTT reagent was used are shown in Table 1 . For two of these reagents, there were TA B L E 2 Factor VIII results obtained with different chromogenic assay kits Results were between 9% and 19% higher than the overall one-stage median for the four samples. As the difference was similar for the two types of Factor VIII, this difference is unlikely to be related to the nature of the FVIII material in the samples but rather to some other aspect of the local assay system such as calibration but with only three users of this method the data should be interpreted cautiously.
| Chromogenic FVIII assay results with different kits
In total, six different kits were used amongst the 27 centres who returned chromogenic FVIII assay results. Results with each commercial kit are shown in Table 2 . Kits which gave results at the upper end of the observed range did so for both types of FVIII.
| Relationship between results obtained by onestage and chromogenic FVIII assay
Results of FVIII assay by one-stage or chromogenic assay are summarized in Table 3 . Factor VIII assay results obtained by one-stage assay were significantly lower (P < 0.001) than those obtained by chromogenic assay for the two samples containing rFVIIIFc. The difference was 22% for the post-infusion sample and 23% for the spiked sample. For the two samples containing Advate, one-stage results were 7% (P < 0.01) and 13% (P < 0.001) lower than chromogenic assay results for the post-infusion and spiked samples, respectively. reported results at the lower end of observed ranges for spiked samples also did so for post-infusion samples, and conversely laboratories who reported at the high end also did so for both spiked and post-infusion samples. This suggests that for both Advate and rFVIIIFc, the two types of material were behaving in a similar way across a range of chromogenic and one-stage assay kits.
| Comparison of spiked samples and postinfusion samples

| Assay design for analysis of postinfusion samples
One-stage assays were used by 91% of responding centres for monitoring products containing plasma derived or full-length recombinant FVIII, with chromogenic assays used in 47% of centres. All chromogenic and one-stage assays used for monitoring Kogenate, Helixate, Advate or Haemate P were calibrated using plasma standards as were chromogenic assays used for monitoring ReFacto AF.
When the one-stage assay was used for monitoring ReFacto AF, one-third of centres calibrated with a plasma standard and twothirds used the RLS for calibration (Table 4) . 
Overall, a fresh calibration curve was prepared using between four and eight different dilutions (median seven with each assay in 12/54 (22%) of the centres who provided details). A stored calibration curve was used by 39 centres (72%) using between three and nine dilutions (median 8). Use of both stored and fresh curves depending on circumstances occurred in 6% of centres. When constructing calibration curves, eight centres (15%) selected FVIII deficient plasma as diluent with the remaining 85% using assay buffer for this purpose. Twenty per cent of centres used only one dilution of test sample during their FVIII assay. by participating centres using a range of methods in our study.
| D ISCUSS I ON
The reasons for this are unknown.
When there is a difference between results obtained with different methods, it is important to consider whether the difference is clinically relevant, and if so which result is more appropriate for patient management purposes. Arguably, the assay used for potency assignment by the drug manufacturer is effectively clinically validated during the studies used to establish efficacious dosing regimens. Any laboratory assay that agrees with the assay used for potency assignment or recovers close to the target based on potency should therefore be clinically safe. Advate potency is assigned using a chromogenic assay in Europe or with a one-stage assay in the United
States. 22 Advate used for both spiking and patient treatment samples was purchased in Europe with potency assignment by chromogenic assay. The potency of rFVIIIFc is assigned by chromogenic assay in both the United States and Europe. 20 To the best of the authors' knowledge, there is currently no consensus on what magnitude of difference between results obtained using different assays should be considered clinically relevant but a number of laboratory field studies have taken the view that divergence of up to 25%-30% from the target may be acceptable for monitoring therapy. 16, 21, 25 It seems likely that the percentage difference that clinicians could accept would depend on the level of Factor VIII in the test sample as a small difference in activity at very low levels translates into a large difference in percentage. However, this may have no clinical relevance (eg, 4 IU/ dL is 33% higher than 3 IU/dL). The impact of using an assay that underestimates activity relative to that used for potency assignment is that there is the potential for costly overtreatment. An assay that underestimates relative to the labelled potency by 20% could lead to an extra 20% of concentrate being infused to achieve a target concentration in the patient. Use of an assay that overestimates relative to potency could lead to under treatment with associated clinical risk.
The present study included a questionnaire about how FVIII assays are constructed as it has been reported that calibration practices and assay design can cause imprecision in assay results and contribute to higher interlaboratory variation in results. 6 Approximately 70%
of centres used a stored calibration curve and 20% used only a single dilution of test sample during their assay, despite recommendations against this practice from some organizations. 1, 29 The interlaboratory variability was similar for one-stage and chromogenic assay results with CVs of 10%-13% and 12%-16%, respectively. There is usually an inverse relationship between the FVIII level and the inter laboratory CV for both one-stage and chromogenic methods, that is, higher CVs at lower levels. 16, 21, 22 In the present study, we observed interlaboratory CVs for samples containing Advate (10%-12%) which TA B L E 4 Concentrates and FVIII:C assays used in different centres were similar to the figures of 10%-18% previously reported in several studies when FVIII activity levels were in the range of 35-80-IU/ dL. 7, 21, 28 As for one-stage assay, there were a number of different reagent sets/kits in use for determination of chromogenic FVIII activity.
There were too few users of chromogenic assay in both the present study and Sommer study 21 to draw robust conclusions about whether different chromogenic kits give different results.
Most recent field studies related to newly developed FVIII concentrates have been performed using mock patient samples constructed in the laboratory by addition/spiking of FVIII concentrate into Factor VIII deficient plasma. 16, 21, 22, 24 It is possible that samples prepared by spiking in vitro may behave differently to genuine ex vivo samples. Indeed, it is well known that some types of spiked samples behave different to ex vivo patient samples in some areas of haemostasis laboratory testing, 30 and for this reason, the International Standards Organization (ISO) requires proficiency testing/external quality assurance (EQA) organizations to use test materials that mimic patient samples as closely as possible. 31 Evidence is therefore needed to assess whether spiked samples can be substituted for post-infusion samples from patients in EQA exercises. In the present study, there was an excellent correlation between results obtained on spiked samples and genuine post-infusion patient samples. If a laboratory obtained a result at the lower end of the observed values on the spiked sample, they also obtained low results on the patient sample, and centres reporting at the high end on one also reported high on the other. This was the case for both Advate and rFVIIIFc suggesting that the 2 types of sample were behaving in a similar way in a number of assay systems. Our study data therefore support the use of spiked samples for EQA/proficiency testing exercises related to these products. Such exercises are the most convenient way to provide postmarketing surveillance of laboratory assay issues.
Our study has some limitations. One limitation of our study is that only samples with FVIII in the 45-60 IU/dL range were included.
Our conclusions could in principle be limited to the levels of FVIII included in our study, so interlaboratory studies incorporating genuine post-infusion samples at lower and higher FVIII activity are needed. External Quality Assessment exercises like the one reported here can contribute to this validation and our data confirm and extend previous studies indicating that several chromogenic and one-stage assay reagent sets can be safely used for monitoring rFVIIIFc or Advate. As assay performance characteristics may change over time, we recommend regular and frequent EQA/proficiency testing for post-infusion monitoring using samples containing all forms of clotting factor concentrate.
|
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